Physician profile
Mark Wallace
NPI 1427098102
$220,972.81
in general payments reported to CMS, 2019-2025
26 companies · $13K in 2025
The $13K reported for 2025 was more than what 96% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68K · 2020: $22K · 2021: $5,416 · 2022: $40K · 2023: $56K · 2024: $15K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $77K · Travel and Lodging: $4,957 · Food and Beverage: $2,118 · Honoraria: $900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $76,879.75 |
| Travel and Lodging | $4,956.59 |
| Food and Beverage | $2,118.33 |
| Honoraria | $900.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $61,921.52 | 2019-2025 | Precision, Wavewriter Alpha Prime 16 |
| Pfizer INC. | $56,495.73 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $23,461.30 | 2019-2024 | |
| Tersera Therapeutics LLC | $18,702.38 | 2019-2025 | Prialt |
| Daiichi Sankyo INC. | $9,917.98 | 2019 | |
| Tonix Medicines, INC. | $8,686.69 | 2025 | |
| Grt US Holding, INC. | $8,520.77 | 2019-2025 | |
| Eli Lilly and Company | $6,563.07 | 2019 | |
| Averitas Pharma INC. | $5,417.57 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $5,116.67 | 2019 | |
| Collegium Pharmaceutical, INC. | $4,000.00 | 2023 | Belbuca, Nucynta, Xtampza |
| Sk Life Science, INC. | $3,200.00 | 2020 | |
| Gw Research Limited | $2,799.50 | 2021 | |
| Masimo Corporation | $2,375.00 | 2020-2021 | |
| Orion Corporation | $1,750.00 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $1,000.00 | 2022 | |
| Abbott Laboratories | $490.21 | 2022-2025 | Proclaim, Eterna |
| Nevro Corp. | $252.86 | 2019-2022 | |
| Medtronic, INC. | $186.97 | 2021-2024 | Intellis Adaptivestim |
| Relievant Medsystems, INC. | $40.48 | 2022 | |
| Avanos Medical | $33.05 | 2022 | |
| Nalu Medical, INC. | $21.83 | 2023 | Nalu Neurostimulation System |
| Abbvie INC. | $19.23 | 2023 | Botox |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.